Jeff Yass’s Context Therapeutics CNTX Stock Holding History

Jeff Yass’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.26K	Sell	16,722 -1,077,172	-98%	-$2.18M	﹤0.01%	13146
2026 Q1	$2.87M	Buy	+1,093,894	New	+$2.55M	﹤0.01%	5358
2025 Q4	–	Sell	-21,967	Closed	-$21.3K	–	12503
2025 Q3	$21.3K	Buy	+21,967	New	+$17.8K	﹤0.01%	12043
2025 Q1	–	Sell	-10,185	Closed	-$10.7K	–	12583
2024 Q4	$10.7K	Sell	10,185 -44,026	-81%	-$76.2K	﹤0.01%	11979
2024 Q3	$106K	Buy	+54,211	New	+$120K	﹤0.01%	11023
2024 Q2	–	Sell	-22,389	Closed	-$30.9K	–	12162
2024 Q1	$30.9K	Buy	+22,389	New	+$25.2K	﹤0.01%	11708
2023 Q2	–	Sell	-24,599	Closed	-$13.8K	–	12185
2023 Q1	$13.8K	Buy	+24,599	New	+$18.6K	﹤0.01%	12141
2022 Q4	–	Sell	-14,137	Closed	-$16K	–	12555
2022 Q3	$16K	Buy	+14,137	New	+$25.4K	﹤0.01%	12666

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Jeff Yass's CNTX Position: Q2 2026 in Review

Jeff Yass reduced its Context Therapeutics (CNTX) stake by 98% in Q2 2026, selling an estimated $2.18M and leaving 16,722 shares worth $9.26K. The position accounts for ﹤0.01% of the portfolio, ranked #13146.

Jeff Yass first reported a position in CNTX in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.87M in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Jeff Yass held 16,722 shares of Context Therapeutics worth $9.26K as of Q2 2026.
Jeff Yass sold 1,077,172 Context Therapeutics shares in Q2 2026, an estimated $2.18M.
Context Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13146 holding.
Jeff Yass first reported a position in Context Therapeutics in Q3 2022 and has held it in 8 quarters since.
Jeff Yass's Context Therapeutics position peaked at $2.87M in Q1 2026.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.